News By: Gary Cramer

It is widely accepted that biosimilars hold the potential to improve patient access to life-changing therapies. However, questions remain about what will be needed to deliver on the promise of greater biosimilar access and affordability. In a recent panel discussion, industry experts weighed in on the state of the biosimilar market, today’s regulatory climate, and what will be required to realize their potential.

Precision medicine has emerged as a game-changer, revolutionizing the landscape of clinical trials and offering new hope for advancement of critical medicines. However, the intricate nature of precision medicine requires precision-based solutions for trial sponsors, clinical research organizations, labs, and research sites. To address the most pressing issues, trial sponsors and research sites must pivot toward precision-based solutions.

Clinical project managers face a range of well-being issues that are unique to their field. These challenges stem from the high-pressure nature of the pharmaceutical and clinical research industry, where the stakes are often very high, and the work can be both demanding and complex. One path forward offers opportunities to find balance and well-being, bringing together the mind, body, and spirit.

A look at some of the numbers, from big to little, that are making a difference in the modern clinical research enterprise.

This paper describes the practice changes that clinical research nurses (CRNs) may anticipate when decentralized clinical trial participation is involved, considering the CRN as a supportive role for clinical nurse care delivery guidance, identifying trial participants, and obtaining safety-related study information to inform care and ethical considerations.